PANEL: Medicines Optimisation - Is this creating health inequalities?

PANEL: Medicines Optimisation - Is this creating health inequalities?

Tuesday, October 1, 2024 11:40 AM to 12:20 PM · 40 min. (Europe/London)

Information

In partnership with Aspire Pharma

  • What is our main focus for improving prescribing?
  • How can we improve efficiency and personalisation of medicines?
  • How are ICB's monitoring health inequalities and how are they addressing them?
  • How do we reduce unwarranted variation, fairer equity to access of medicines and improve patients experience?
  • How do we collaborate and foster engagement from relevant stakeholders
  • What would it take to have a national formulary to aid the reduction of health inequalities?
Aspire PharmaNetworking AreaEstablished in 2009, Aspire Pharma continues to be one of the fastest growing pharmaceutical companies in the UK. Supplying a range of pharmaceuticals and medical devices across multiple channels, Aspire’s products are carefully selected to deliver value and differentiation to both patients and prescribers. With the recent acquisition of Morningside Pharmaceuticals and Healthcare, complimenting impressive organic growth, Aspire continues to focus on extending its portfolio of innovative products, as well as furthering its position across 8 core therapeutic areas. With a wide range of branded and generic products able to deliver significant efficiencies while supporting the wider NHS green agenda, Aspire provide a wealth of resources and tools that can be implemented at locality level, to further support these goals.